Navigation Links
Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
Date:6/9/2008

effects. These data, along with the significant improvements on bioavailability and pharmacodynamic effects with PI-2301, provide further evidence that PI-2301 may replace Copaxone as first-line therapy in relapsing remitting multiple sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301 to maximize the therapeutic benefit of a proven, safe compound class in multiple sclerosis as well as increasing patients' convenience."

PI-2301 is a second generation peptide copolymer from a similar compound class as Copaxone. PI-2301 works through immune modulation by enhancing the regulatory response of the immune system to control the pathogenic autoimmune response in certain diseases. PI-2301 has been optimized using Peptimmune's novel platform peptide chemistry and in pre-clinical studies, has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in pre-clinical models of autoimmune diseases where immune modulation may be effective, such as Crohn's disease, rheumatoid arthritis and autoimmune uveitis. Peptimmune has also introduced highly reproducible manufacturing methods that allow very strict control and characterization of PI-2301 and should provide a superior level of batch to batch consistency.

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide. MS is an autoimmune disease in which the individuals' immune system responds against multiple components of nerve-insulating myelin. The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of peptide therapies to improve the management of chronic autoimmune and inflammato
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
4. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
8. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
11. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Influenza will affect as many as 200,000 people this year ... as high as 49,000 people.  The main way ... to person in respiratory droplets of coughs and sneezes. ... kills much fewer people each year than the Flu. The ... sweat, saliva, blood and other bodily fluids. The Ebola virus ...
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... The Society for Biomolecular Sciences, now officially the ... and Screening (SLAS), invites students, graduate students, post-doctoral associates ... Travel Award to be used for the SBS 17th ... FL, USA. Applicants must be the primary ...
... Nov. 4, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Conference in Phoenix, Arizona on Thursday, November 11, 2010 at ... M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, ... be webcast live through the "Investors" section of Amylin,s corporate ...
Cached Medicine Technology:Applications Now Being Accepted for SBS 17th Annual Conference & Exhibition Academic Travel Awards 2
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... drinking among young adult men may lead to increased blood ... didn,t cause a similar rise in blood pressure for young ... fact, when young adult women drank lightly or moderately, their ... study found. "This finding parallels studies in older adult ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... , SINGAPORE, June 4 /PRNewswire-Asia/ ... industry will have a unique platform to gain business ... and Congress,2009. According to market analysts, the medical tourism ... market alone will generate revenue,of more than US$4.4 billion ...
... 4 Abbott (NYSE: ABT ) and ... New Drug Application (NDA) to the U.S. Food and ... treatment of mixed dyslipidemia, a combination of two or ... cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). ...
... Sheets: GOHE) announced today that the company has entered into a ... of a source of high pH water from a premier aquifer. ... annually of this healthy water. , , The water has ... significant natural anti oxidants. , , Charlie Caudle, CEO of ...
... June 4 /PRNewswire/ -- US Oncology, ... aggregate principal amount of senior secured notes to qualified institutional ... of 1933, as amended (the "Securities Act") and outside the ... Act. , , The company plans to use the ...
... 4 Prescribing Reference LLC is pleased to announce that the ... medical professionals as a free download for ... www.empr.com/download ). The MPR Mobile & Desktop Edition ... Microsoft Vista. , , For over 24 years, medical professionals ...
... Advisors, MISSION Skincare(TM) , , NEW YORK, June 4 ... skincare products, is pleased to announce that Brian B. Adams, ... of the world,s most-esteemed athletes as the latest addition to ... of the Board of Advisors, Dr. Adams will play an ...
Cached Medicine News:Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 2Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 4Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 5Health News:Go Healthy Enters Letter of Intent to Acquire Premium Water Source 2Health News:US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering 2Health News:MPR Drug Database Available as a Free Download for Mobile Devices, Including BlackBerry and Palm 2Health News:Dr. Brian B. Adams to Join the 'MISSION' 2Health News:Dr. Brian B. Adams to Join the 'MISSION' 3
...
... on decades of experience, the SSD-1000 is ... system. It uses our advanced technologies and ... Using the same technology as our more ... capabilities in a compact and mobile setting., ...
... Harmonic Echo technology constructs images using ... less artifacts and noise than fundamental-frequency ... technology to transmit distortion-free, fundamental-frequency ultrasound ... beam is a pure sinusoidal wave, ...
... Topical Skin Adhesive gives you new options ... intended for topical application only to hold ... from surgical incisions, including punctures from minimally ... lacerations. DERMABOND adhesive may be used in ...
Medicine Products: